New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2013
17:37 EDTOGXIOncoGenex CFO Michelle Burris resigns from position, to leave company March 31
OncoGenex disclosed in a regulatory filing that in early January, Scott Cormack, president and CEO, and Michelle Burris, executive VP of operations, CFO, principal accounting officer, treasurer and secretary, disclosed to the company’s board that they have a developing personal relationship with one another that warranted consideration of their reporting relationship and duties. After consideration and discussion by the independent members of the company’s board, as well as consultations with Cormack and Burris, the company’s board determined that it would be advisable for Burris to transfer her executive duties to others and to continue portions of her work in operations as a consultant to the company, reporting directly to the board. On February 1 Burris resigned as the company’s principal accounting officer, CFO, secretary and treasurer. From February 1 to March 31, Burris will continue to serve as the company’s executive VP of operations. Effective March 31, Burris will resign as the company’s executive VP of operations, and the company has agreed to pay all wages, bonuses, vacation, reimbursable expenses and similar payments due to Burris as of such date. On January 31 the company’s board appointed Cormack as the company’s principal financial officer, secretary and treasurer and Susan Wyrick as the company’s principal accounting officer, effective February 1.
News For OGXI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
06:32 EDTOGXIOncoGenex completes patient enrollment in Phase 3 AFFINITY trial
OncoGenex Pharmaceuticals announced that patient enrollment has been completed in the Phase 3 AFFINITY trial. The international, randomized, open-label Phase 3 AFFINITY trial is designed to evaluate the potential of custirsen to improve survival outcomes in approximately 630 men with metastatic castrate-resistant prostate cancer. Patients have been randomized to receive second-line Jevtana and prednisone with or without custirsen.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use